Revolution Medicines Inc (RVMD) - Total Liabilities
Based on the latest financial reports, Revolution Medicines Inc (RVMD) has total liabilities worth $1.72 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check RVMD cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Revolution Medicines Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Revolution Medicines Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see RVMD total assets.
Revolution Medicines Inc Competitors by Total Liabilities
The table below lists competitors of Revolution Medicines Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WEG S.A.
SA:WEGE3
|
Brazil | R$26.48 Billion |
|
Adani Power Limited
NSE:ADANIPOWER
|
India | Rs758.78 Billion |
|
Infosys Limited
F:IOY
|
Germany | €6.61 Billion |
|
KB Financial Group
KO:105560
|
Korea | ₩768.60 Trillion |
|
Entergy Corporation
NYSE:ETR
|
USA | $52.87 Billion |
|
RWE Aktiengesellschaft
F:RWEA
|
Germany | €60.15 Billion |
|
Argen-X
F:1AE
|
Germany | €1.36 Billion |
Liability Composition Analysis (2017–2025)
This chart breaks down Revolution Medicines Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Revolution Medicines Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.38 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Revolution Medicines Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Revolution Medicines Inc (2017–2025)
The table below shows the annual total liabilities of Revolution Medicines Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $723.21 Million | +146.75% |
| 2024-12-31 | $293.10 Million | +24.45% |
| 2023-12-31 | $235.51 Million | +85.82% |
| 2022-12-31 | $126.74 Million | -6.41% |
| 2021-12-31 | $135.42 Million | +46.04% |
| 2020-12-31 | $92.72 Million | +36.37% |
| 2019-12-31 | $67.99 Million | -8.03% |
| 2018-12-31 | $73.93 Million | +601.00% |
| 2017-12-31 | $10.55 Million | -- |
About Revolution Medicines Inc
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS comp… Read more